Literature DB >> 21037216

Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders.

Samuli I Saarni1, Satu Viertiö, Jonna Perälä, Seppo Koskinen, Jouko Lönnqvist, Jaana Suvisaari.   

Abstract

BACKGROUND: Health utility and quality of life (QoL) are increasingly important outcome measures in healthcare and health economics. AIMS: To compare the loss of subjective QoL and utility-based health-related quality of life (HRQoL) associated with psychotic disorders.
METHOD: A representative sample of 8028 Finns was screened for psychotic disorders and bipolar I disorder. Lifetime psychotic disorders were diagnosed using the Structured Clinical Interview for DSM-IV and/or case records. Health-related quality of life was measured with EQ-5D and 15D, and QoL was measured with a 10-point scale.
RESULTS: Schizoaffective disorder was associated with the largest losses of QoL and HRQoL, with bipolar I disorder associated with similar or smaller losses than schizophrenia. Current depressive symptoms explained most of the losses.
CONCLUSIONS: Depressive symptoms are the strongest predictors of poor QoL/HRQoL in psychotic disorders. Subjective loss of QoL associated with psychotic disorders may be smaller than objective loss of functioning suggests. The EQ-5D is problematic as an outcome measure in psychotic disorders.

Entities:  

Mesh:

Year:  2010        PMID: 21037216     DOI: 10.1192/bjp.bp.109.076489

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  57 in total

1.  Sedentary Behavior and Quality of Life in People with Psychotic Disorders from a Low Income Country: A Study from Uganda.

Authors:  Davy Vancampfort; Michel Probst; Simon Rosenbaum; Philip B Ward; Tine Van Damme; James Mugisha
Journal:  Community Ment Health J       Date:  2018-12-05

Review 2.  Utility scores for different health states related to depression: individual participant data analysis.

Authors:  Spyros Kolovos; Judith E Bosmans; Johanna M van Dongen; Birre van Esveld; Dorcas Magai; Annemieke van Straten; Christina van der Feltz-Cornelis; Kirsten M van Steenbergen-Weijenburg; Klaas M Huijbregts; Harm van Marwijk; Heleen Riper; Maurits W van Tulder
Journal:  Qual Life Res       Date:  2017-03-04       Impact factor: 4.147

3.  Conceptualization and treatment of negative symptoms in schizophrenia.

Authors:  Sonali Sarkar; Kiley Hillner; Dawn I Velligan
Journal:  World J Psychiatry       Date:  2015-12-22

4.  Which is A More Debilitating Disorder Schizophrenia or Dysthymia? - A Comparative Study.

Authors:  Shaunak A Ajinkya; Pradeep R Jadhav; Shruti Rajamani
Journal:  J Clin Diagn Res       Date:  2015-05-01

5.  Contribution of attachment insecurity to health-related quality of life in depressed patients.

Authors:  Alexander M Ponizovsky; Angela Drannikov
Journal:  World J Psychiatry       Date:  2013-06-22

6.  The impact of experienced discrimination and self-stigma on sleep and health-related quality of life among individuals with mental disorders in Hong Kong.

Authors:  Kevin Ka Shing Chan; Winnie Tsz Wa Fung
Journal:  Qual Life Res       Date:  2019-04-16       Impact factor: 4.147

Review 7.  Posttraumatic stress disorder, depression, and health-related quality of life in patients with bipolar disorder: review and new data from a multi-site community clinic sample.

Authors:  Laura A Bajor; Zongshan Lai; David E Goodrich; Christopher J Miller; Robert B Penfold; Hyungjin Myra Kim; Mark S Bauer; Amy M Kilbourne
Journal:  J Affect Disord       Date:  2012-09-27       Impact factor: 4.839

8.  Symptom dimensions and functional impairment in early psychosis: more to the story than just negative symptoms.

Authors:  Daniel Fulford; Tara A Niendam; Erin G Floyd; Cameron S Carter; Daniel H Mathalon; Sophia Vinogradov; Barbara K Stuart; Rachel L Loewy
Journal:  Schizophr Res       Date:  2013-04-12       Impact factor: 4.939

9.  Epidemiological and clinical characterization following a first psychotic episode in major depressive disorder: comparisons with schizophrenia and bipolar I disorder in the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS).

Authors:  Olabisi Owoeye; Tara Kingston; Paul J Scully; Patrizia Baldwin; David Browne; Anthony Kinsella; Vincent Russell; Eadbhard O'Callaghan; John L Waddington
Journal:  Schizophr Bull       Date:  2013-05-28       Impact factor: 9.306

10.  Lower glutamic acid decarboxylase 65-kDa isoform messenger RNA and protein levels in the prefrontal cortex in schizoaffective disorder but not schizophrenia.

Authors:  Jill R Glausier; Sohei Kimoto; Kenneth N Fish; David A Lewis
Journal:  Biol Psychiatry       Date:  2014-05-29       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.